KEGG   DRUG: Necitumumab
Entry
D10018                      Drug                                   
Name
Necitumumab (USAN/INN);
Necitumumab (genetical recombination) (JAN);
Portrazza (TN)
Product
PORTRAZZA (Eli Lilly and Company)
Sequence
(Heavy chain)
QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SGDYYWSWIR QPPGKGLEWI GYIYYSGSTD
YNPSLKSRVT MSVDTSKNQF SLKVNSVTAA DTAVYYCARV SIFGVGTFDY WGQGTLVTVS
SASTKGPSVL PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
(Light chain)
EIVMTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
RFSGSGSGTD FTLTISSLEP EDFAVYYCHQ YGSTPLTFGG GTKAEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H97, H148-H204, H224-L214, H230-H'230, H233-H'233, H265-H325, H371-H429, H'22-H'97, H'148-H'204, H'224-L'214, H'265-H'325, H'371-H'429, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03162  EGFR inhibitor
Remark
Therapeutic category: 4291
ATC code: L01FE03
Product: D10018<JP/US>
Efficacy
Antineoplastic, Receptor tyrosine kinase inhibitor, Anti-epidermal growth factor receptor antibody
  Disease
Squamous non-small cell lung cancer [DS:H00014]
  Type
Monoclonal antibody
Target
EGFR [HSA:1956] [KO:K04361]
  Pathway
hsa04010  MAPK signaling pathway
hsa04012  ErbB signaling pathway
hsa05223  Non-small cell lung cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
     L01FE03 Necitumumab
      D10018  Necitumumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Necitumumab
    D10018  Necitumumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10018  Necitumumab (USAN/INN); Necitumumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03162  EGFR inhibitor
     D10018  Necitumumab
Drug classes [BR:br08332]
 Antineoplastic
  DG03162  EGFR inhibitor
   D10018  Necitumumab
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    EGFR
     D10018  Necitumumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10018
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10018
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10018
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10018
Other DBs
PubChem: 135626739
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system